"pancreatic tumor progression" trang 13 - tải miễn phí từ tailieuXANH
Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells

Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells
15    64    0
An elevated expression of serum exosomal microRNA-191, − 21, −451a of pancreatic neoplasm is considered to be efficient diagnostic marker

An elevated expression of serum exosomal microRNA-191, − 21, −451a of pancreatic neoplasm is considered to be efficient diagnostic marker
11    68    0
Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer

Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer
12    66    0
MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma

MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma
14    93    0
Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes

Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes
13    73    0
Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps

Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps
12    63    0
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
10    67    0
Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study

Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study
11    72    0
Long-term trends in pancreatic cancer mortality in Spain (1952–2012)

Long-term trends in pancreatic cancer mortality in Spain (1952–2012)
10    75    0
Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: A phase II study

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: A phase II study
7    103    0
Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma

Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma
10    89    0
Non-invasively predicting differentiation of pancreatic cancer through comparative serum metabonomic profiling

Non-invasively predicting differentiation of pancreatic cancer through comparative serum metabonomic profiling
11    106    0
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing firstline gemcitabine-containing therapy: Effect of performance status and comparison with other regimens

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing firstline gemcitabine-containing therapy: Effect of performance status and comparison with other regimens
9    89    0
Study protocol for an open-label, singlearm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma

Study protocol for an open-label, singlearm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
8    103    0
Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox

Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
10    124    0
Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: Implications for translational research

Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: Implications for translational research
5    87    0
Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells

Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells
10    108    0
Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells

Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells
12    72    0
Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations

Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations
15    71    0
Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models

Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models
13    93    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.